专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2017087588A1 CTLA4 BINDERS 审中-公开
公开(公告)号：WO2017087588A1
公开(公告)日：2017-05-26
申请号：PCT/US2016/062393
申请日：2016-11-17
申请人： MERCK SHARP & DOHME CORP. , PUNNONEN, Juha , BEAUMONT, Maribel , BUYSE, Marie-Ange , BOUTTON, Carlo , DOMBRECHT, Bruno , VICTOR, Bjorn
发明人： PUNNONEN, Juha , BEAUMONT, Maribel , BUYSE, Marie-Ange , BOUTTON, Carlo , DOMBRECHT, Bruno , VICTOR, Bjorn
IPC分类号： C07K16/18 , C07K16/28 , A61K39/395
CPC分类号： C07K16/2818 , A61K39/3955 , A61K39/39558 , A61K2039/505 , A61K2039/54 , A61K2039/545 , C07K14/765 , C07K16/18 , C07K2317/22 , C07K2317/24 , C07K2317/31 , C07K2317/32 , C07K2317/33 , C07K2317/34 , C07K2317/35 , C07K2317/565 , C07K2317/569 , C07K2317/62 , C07K2317/76 , C07K2317/92 , C07K2319/31
摘要： The present invention provides molecules, such as ISVDs and Nanobodies, that bind to CTLA4 or human serum albumin. These molecules have been engineered so as to reduce the incidence of binding by pre-existing antibodies in the bodies of a subject administered such a molecule. Methods for increasing immune response, treating cancer and/or treating an infectious disease with such molecules are provided.
摘要翻译：本发明提供了结合CTLA4或人血清白蛋白的分子，例如ISVD和纳米抗体。已经对这些分子进行了工程改造，从而降低施用这种分子的受试者体内预先存在的抗体的结合发生率。提供了增加免疫应答，治疗癌症和/或用这些分子治疗感染性疾病的方法。

2. 发明申请

WO2008070583A3 THROMBOPOIETIN MIMETICS 审中-公开
标题翻译： THROMBOPOIETINMIMTCS
公开(公告)号：WO2008070583A3
公开(公告)日：2008-08-14
申请号：PCT/US2007086186
申请日：2007-11-30
申请人： STATEGICS INC , SPENCER JEFFREY R , PUNNONEN JUHA
发明人： SPENCER JEFFREY R , PUNNONEN JUHA
IPC分类号： A61K31/655
CPC分类号： C07D231/46 , C07D401/12
摘要： The invention relates to compounds and their use in the treatment of thrombocytopenia resulting from diseases or conditions such as immune thrombocytopenic purpura, cancer chemotherapy, surgery, bone marrow or stem cell transplantation, radiation injury or treatment, chronic viral infection, and pancytopenia. The invention further relates to pharmaceutical compositions containing the compounds and compositions of the invention as well as methods for treating such diseases or conditions in a mammal, including a human, by administering to such mammal an effective amount of a selected thrombopoietin receptor agonist.
摘要翻译：本发明涉及化合物及其在治疗由免疫性血小板减少性紫癜，癌症化疗，手术，骨髓或干细胞移植，放射性损伤或治疗，慢性病毒感染和全血细胞减少等疾病或病症引起的血小板减少症中的用途。本发明进一步涉及含有本发明化合物和组合物的药物组合物，以及通过向该哺乳动物施用有效量的选择的血小板生成素受体激动剂来治疗哺乳动物（包括人）中的这些疾病或病症的方法。

3. 发明申请

WO1994004658A1 METHODS FOR MATURING PRECURSOR B CELLS 审中-公开
标题翻译：用于成熟前体B细胞的方法
公开(公告)号：WO1994004658A1
公开(公告)日：1994-03-03
申请号：PCT/US1993007644
申请日：1993-08-18
申请人： SCHERING CORPORATION , DE VRIES, Jan , PUNNONEN, Juha
发明人： SCHERING CORPORATION
IPC分类号： C12N05/08
CPC分类号： C12N5/0635 , C12N2500/25 , C12N2500/36 , C12N2502/11
摘要： The present invention provides for a method of inducing differentiation of precursor B cells to immunoglobulin (Ig)-secreting cells comprising contacting said precursor B cells with an aqueous medium comprised of IL-4 and a contact mediated signal provided by optimally activated CD4+ cells. The present invention further provides for a method of inducing differentiation of precursor B cells to immunoglobulin (Ig)-secreting cells comprising contacting said percursor B cells with an aqueous medium comprised of IL-4, IL-7 and a contact mediated signal provided by non-optimally activated CD4+ cells.
摘要翻译：本发明提供诱导前体B细胞分化为免疫球蛋白（Ig）分泌细胞的方法，包括使所述前体B细胞与由IL-4组成的水性介质和由最佳活化的CD4 +细胞提供的接触介导信号接触。本发明进一步提供诱导前体B细胞分化为免疫球蛋白（Ig）分泌细胞的方法，其包括使所述血管B细胞与由IL-4，IL-7组成的水介质和由非 - - 最佳活化的CD4 +细胞。

4. 发明申请

WO2020185722A2 ANTI-CANCER COMBINATION THERAPIES COMPRISING CTLA-4 AND PD-1 BLOCKING AGENTS 审中-公开
公开(公告)号：WO2020185722A2
公开(公告)日：2020-09-17
申请号：PCT/US2020/021783
申请日：2020-03-10
申请人： MERCK SHARP & DOHME CORP. , LAFACE, Drake , PUNNONEN, Juha , BOWMAN, Edward , BAUCHE, David , CHACKERIAN, Alissa , GREIN, Jeffery , MAUZE, Smita , SAWANT, Anandi , ANNAMALAI, Lakshmanan
发明人： LAFACE, Drake , PUNNONEN, Juha , BOWMAN, Edward , BAUCHE, David , CHACKERIAN, Alissa , GREIN, Jeffery , MAUZE, Smita , SAWANT, Anandi , ANNAMALAI, Lakshmanan
IPC分类号： A61K39/395
摘要： Anti-cancer combination therapies comprising a CTLA-4 blocking agent and a PD-1 blocking agent are disclosed. In particular, combination therapies are disclosed wherein the CTLA-4 blocking agent is an effector-silent anti-CTLA-4 antibody or effector-silent anti-CTLA-4 antibody fragment and the PD-1 blocking agent is an anti- PD-1 or anti-PD-L1 antibody, or antibody fragment thereof.

5. 发明申请

WO2008070583A2 THROMBOPOIETIN MIMETICS 审中-公开
公开(公告)号：WO2008070583A2
公开(公告)日：2008-06-12
申请号：PCT/US2007/086186
申请日：2007-11-30
申请人： STATEGICS, INC. , SPENCER, Jeffrey, R. , PUNNONEN, Juha
发明人： SPENCER, Jeffrey, R. , PUNNONEN, Juha
IPC分类号： C07D401/10 , C07D231/46 , A61K31/454 , A61K31/4152 , A61P25/00 , A61P9/00
CPC分类号： C07D231/46 , C07D401/12
摘要： The invention relates to compounds and their use in the treatment of thrombocytopenia resulting from diseases or conditions such as immune thrombocytopenic purpura, cancer chemotherapy, surgery, bone marrow or stem cell transplantation, radiation injury or treatment, chronic viral infection, and pancytopenia. The invention further relates to pharmaceutical compositions containing the compounds and compositions of the invention as well as methods for treating such diseases or conditions in a mammal, including a human, by administering to such mammal an effective amount of a selected thrombopoietin receptor agonist.
摘要翻译：本发明涉及化合物及其在治疗由诸如免疫性血小板减少性紫癜，癌症化疗，手术，骨髓或干细胞移植，放射损伤或治疗，慢性疾病或病症等疾病或病症引起的血小板减少症中的用途。病毒感染和全血细胞减少症。本发明进一步涉及含有本发明化合物和组合物的药物组合物，以及通过给予这种哺乳动物有效量的选择性血小板生成素受体激动剂治疗哺乳动物（包括人）的此类疾病或病症的方法。 p>

6. 发明申请

WO03102166A8 NOVEL FLAVIVIRUS ANTIGENS 审中-公开
标题翻译：新型FLAVIVIRUS抗原
公开(公告)号：WO03102166A8
公开(公告)日：2004-11-11
申请号：PCT/US0305918
申请日：2003-02-26
申请人： MAXYGEN INC , APT DORIS , PUNNONEN JUHA , BRINKMAN ALICE M
发明人： APT DORIS , PUNNONEN JUHA , BRINKMAN ALICE M
IPC分类号： A61K39/00 , C07H21/04 , C07K14/01 , C07K14/18 , C12N5/06 , C12N15/86 , C12P21/02 , C12Q1/70 , A61K39/12 , C12P21/06
CPC分类号： A61K39/12 , A61K39/00 , A61K2039/5258 , A61K2039/53 , A61K2039/54 , A61K2039/545 , A61K2039/57 , C07K14/005 , C07K14/05 , C07K2319/00 , C07K2319/02 , C12N7/00 , C12N15/86 , C12N2750/14143 , C12N2770/24122 , C12N2770/24123 , C12N2770/24134 , C12N2770/24171
摘要： The invention provides polynucleotides and polypeptides encoded therefrom having advantageous properties, including an ability to induce an immune response to flaviviruses. The polypeptides and polynucleotides of the invention are useful in methods of inducing immune response against flaviviruses, including dengue viruses. Compositions and methods for utilizing polynucleotides and polypeptides of the invention are also provided.
摘要翻译：本发明提供了由其编码的多核苷酸和多肽，其具有有利的性质，包括诱导对黄病毒的免疫应答的能力。本发明的多肽和多核苷酸可用于诱导针对黄病毒的免疫应答的方法，包括登革热病毒。还提供了用于利用本发明的多核苷酸和多肽的组合物和方法。

7. 发明申请

WO0200897A3 NOVEL CHIMERIC PROMOTERS 审中-公开
标题翻译：新的嵌入式启动器
公开(公告)号：WO0200897A3
公开(公告)日：2002-08-15
申请号：PCT/US0120123
申请日：2001-06-21
申请人： MAXYGEN INC , PUNNONEN JUHA , WRIGHT ANNE , SEMYONOV ANDREY
发明人： PUNNONEN JUHA , WRIGHT ANNE , SEMYONOV ANDREY
IPC分类号： C12N15/10 , C12N15/67 , C12N15/85 , C12Q1/68 , G06F19/22 , C12N15/38 , A61K48/00 , C12N5/10
CPC分类号： C12N15/1058 , C12N15/1034 , C12N15/1086 , C12N15/67 , C12N15/85 , C12N2800/108 , C12Q1/6837 , G06F19/22
摘要： The invention provides novel chimeric promoter/enhancers. The chimeric promoter/enhancers are particularly suitable for directing gene expression in mammalian cells.
摘要翻译：本发明提供了新的嵌合启动子/增强子。嵌合启动子/增强子特别适用于指导哺乳动物细胞中的基因表达。

8. 发明申请

WO2009058564A3 IMMUNOSUPPRESSIVE POLYPEPTIDES AND NUCLEIC ACIDS 审中-公开
标题翻译：免疫抑制多肽和核酸
公开(公告)号：WO2009058564A3
公开(公告)日：2010-01-14
申请号：PCT/US2008079981
申请日：2008-10-15
申请人： MAXYGEN INC , KARRER ERIK E , PAIDHUNGAT MADAN M , BASS STEVEN H , NEIGHBORS MARGARET , PUNNONEN JUHA , CHAPIN STEVEN J , VISWANATHAN SRIDHAR , LARSEN BRENT R
发明人： KARRER ERIK E , PAIDHUNGAT MADAN M , BASS STEVEN H , NEIGHBORS MARGARET , PUNNONEN JUHA , CHAPIN STEVEN J , VISWANATHAN SRIDHAR , LARSEN BRENT R
IPC分类号： C07K14/705
CPC分类号： C07K14/70521 , C07K2319/30
摘要： The invention provides immunosuppressive polypeptides and nucleic acids encoding such polypeptides. In one aspect, the invention provides mutant CTLA-4 polypeptides and nucleic acids encoding mutant CTLA-4 polypeptides. Compositions and methods for utilizing such polypeptides and nucleic acids are also provided.
摘要翻译：本发明提供免疫抑制多肽和编码这种多肽的核酸。一方面，本发明提供突变CTLA-4多肽和编码突变CTLA-4多肽的核酸。还提供了用于利用这些多肽和核酸的组合物和方法。

9. 发明申请

WO2009058564A2 IMMUNOSUPPRESSIVE POLYPEPTIDES AND NUCLEIC ACIDS 审中-公开
标题翻译：免疫抑制多肽和核酸
公开(公告)号：WO2009058564A2
公开(公告)日：2009-05-07
申请号：PCT/US2008/079981
申请日：2008-10-15
申请人： MAXYGEN, INC. , KARRER, Erik, E. , PAIDHUNGAT, Madan, M. , BASS, Steven, H. , NEIGHBORS, Margaret , PUNNONEN, Juha , CHAPIN, Steven, J. , VISWANATHAN, Sridhar , LARSEN, Brent, R.
发明人： KARRER, Erik, E. , PAIDHUNGAT, Madan, M. , BASS, Steven, H. , NEIGHBORS, Margaret , PUNNONEN, Juha , CHAPIN, Steven, J. , VISWANATHAN, Sridhar , LARSEN, Brent, R.
IPC分类号： C07K16/00 , C07K14/705
CPC分类号： C07K14/70521 , C07K2319/30
摘要： The invention provides immunosuppressive polypeptides and nucleic acids encoding such polypeptides. In one aspect, the invention provides mutant CTLA-4 polypeptides and nucleic acids encoding mutant CTLA-4 polypeptides. Compositions and methods for utilizing such polypeptides and nucleic acids are also provided.
摘要翻译：本发明提供免疫抑制多肽和编码这种多肽的核酸。一方面，本发明提供突变CTLA-4多肽和编码突变CTLA-4多肽的核酸。还提供了用于利用这些多肽和核酸的组合物和方法。

10. 发明申请

WO2004029197A2 NOVEL CO-STIMULATORY MOLECULES 审中-公开
标题翻译：新型辅助分子
公开(公告)号：WO2004029197A2
公开(公告)日：2004-04-08
申请号：PCT/US0219898
申请日：2002-06-21
申请人： MAXYGEN INC , PUNNONEN JUHA , LAZETIC ALEXANDRA L L , LEONG STEVEN R , CHANG JEAN CHIA-CHUN , APT DORIS , GUSTAFSSON CLAES
发明人： PUNNONEN JUHA , LAZETIC ALEXANDRA L L , LEONG STEVEN R , CHANG JEAN CHIA-CHUN , APT DORIS , GUSTAFSSON CLAES
IPC分类号： A61K38/00 , A61K38/17 , C07K14/705 , C12N15/12 , C12Q1/68 , C12N
CPC分类号： C07K14/70503 , A61K38/00 , C07K14/70532
摘要： The invention provides polynucleotides and polypeptides encoded therefrom having advantageous properties, including an ability of the polypeptides to preferentially bind a human CD28 or CTLA-4 receptor at a level greater or less than the ability of human B7-1 to bind human CD28 or CTLA-4, or to induce or inhibit altered level of T cell proliferation response greater compared to that generated by human B7-1. The polypeptides and polynulceotides of the invention are useful in therapeutic and prophylactic treatment methods, gene therapy applications, and vaccines.
摘要翻译：本发明提供了由其编码的多核苷酸和多肽，其具有有利的性质，包括多肽以大于或小于人B7-1结合人CD28或CTLA-4受体的能力优先结合人CD28或CTLA-4受体的能力， 4，或诱导或抑制T细胞增殖反应的改变水平与人B7-1产生的相比更大。本发明的多肽和多核苷酸可用于治疗和预防性治疗方法，基因治疗应用和疫苗。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式